恒瑞医药：SHR-2906注射液获得药物临床试验批准

Core Viewpoint - The announcement indicates that the subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of SHR-2906 injection, a self-developed therapeutic biological product aimed at weight control and metabolic regulation [1] Group 1: Product Development - SHR-2906 injection is expected to have a synergistic effect in reducing energy intake and promoting energy expenditure, thereby regulating glucose and lipid metabolism and controlling weight [1] - The product aims to improve the metabolic environment in the body and is anticipated to demonstrate clinical efficacy in treating overweight and obesity [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]